Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

954
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
954
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

755
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
755
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.

Therapeutic advances in gastroenterology·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.

Inflammatory bowel diseases·2026
Same author

Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.

Gut·2026
Same author

Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.

Inflammatory bowel diseases·2025
Same author

Inflammatory Bowel Disease Advice Lines: A Scoping Review.

Crohn's & colitis 360·2025
Same journal

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 2: ulcerative colitis.

Frontline gastroenterology·2026
Same journal

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease.

Frontline gastroenterology·2026
Same journal

Recent advances in the diagnosis and management of amoebiasis.

Frontline gastroenterology·2026
Same journal

Optimising triage of urgent referrals for suspected IBD: results from the Birmingham IBD inception study.

Frontline gastroenterology·2025
Same journal

Liver transplant assessment for hepatocellular carcinoma: a single-centre experience.

Frontline gastroenterology·2025
Same journal

Correction: Recent advances in the diagnosis and management of amoebiasis.

Frontline gastroenterology·2025
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

517

The future developments in inflammatory bowel disease care.

Peter Irving

    Frontline Gastroenterology
    |August 26, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Inflammatory bowel disease (IBD) care is advancing with new treatments and services. Innovative solutions are needed to balance specialist care with community-based approaches amidst economic challenges in the UK.

    More Related Videos

    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
    06:57

    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

    Published on: September 18, 2016

    9.7K
    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
    07:38

    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

    Published on: September 13, 2016

    8.8K

    Related Experiment Videos

    Last Updated: Feb 24, 2026

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
    09:44

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

    Published on: October 14, 2025

    517
    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
    06:57

    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

    Published on: September 18, 2016

    9.7K
    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
    07:38

    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

    Published on: September 13, 2016

    8.8K

    Area of Science:

    • Gastroenterology and Hepatology
    • Health Services Research
    • Public Health Policy

    Background:

    • Inflammatory Bowel Disease (IBD) care has seen significant advancements over the past decade.
    • Recent innovations in therapeutics and service delivery promise further improvements.
    • The UK faces economic challenges and National Health Service (NHS) reforms impacting IBD service provision.

    Purpose of the Study:

    • To analyze the evolving landscape of Inflammatory Bowel Disease (IBD) care.
    • To identify challenges and opportunities in IBD service provision within the UK.
    • To explore strategies for integrating specialist IBD care with community-based models.

    Main Methods:

    • Review of recent therapeutic innovations in IBD management.
    • Analysis of current IBD service models and their challenges.
    • Exploration of technological advancements in healthcare communication and delivery.

    Main Results:

    • IBD care has evolved significantly, with ongoing therapeutic and service innovations.
    • Economic downturn and NHS reforms pose considerable challenges to UK IBD services.
    • Balancing specialist and community-based care requires innovative solutions.

    Conclusions:

    • Future IBD care improvements are anticipated due to therapeutic and technological advancements.
    • Navigating economic and healthcare system reforms is crucial for sustained IBD service provision.
    • Technological integration and creative strategies are essential for optimizing IBD care delivery, particularly in balancing specialist and community settings.